As cancer treatments become increasingly personalized and complex, the value of real-world evidence (RWEF) has grown significantly. To better understand how oncologists are integrating RWEF into their clinical decision-making processes, we surveyed 50 Canadian and 100 American oncologists. The results highlight not only the growing importance of RWEF in practice, but also key areas where pharmaceutical companies can play a more active and sustained role.
The majority of oncologists surveyed—86% in Canada and 90% in the United States—reported using clinical practice modeling (CPM) at least occasionally to guide their treatment decisions. Among them, more than half of Canadian oncologists (56%) and half of American oncologists (50%) reported using it often or almost always. This suggests that real-world data have become an essential component of routine clinical decision-making and presents an opportunity for pharmaceutical companies to ensure that the CPMs they generate are not only rigorous but also directly relevant to clinical practice.
Les infographiques peuvent contenir certaines conclusions de nos études indépendantes. Contactez-nous pour savoir si votre organisation peut bénéficier d’une présentation gratuite avec accès au rapport complet.
Prêt à découvrir comment les données peuvent accélérer vos recherches pharmaceutiques ? Contactez notre équipe pour discuter de vos objectifs.
